Carolyne Zimmerman

General Partner dRx Capital

DSC_0605 (1)

Carolyne is General Partner at dRx Capital, a joint investment company between Novartis Pharmaceuticals and Qualcomm Ventures , a $100M venture investment firm focusing on early stage companies in the digital medicine space. dRx’s current portfolio includes investments in Omada Health and Science37.

Prior, Carolyne spent the past 12 years with Novartis Pharmaceutical’s Global Business Development and Licensing Group, most recently leading the Business Development and Licensing efforts for the Global Cardio-Metabolic Franchise where she was responsible for securing strategic assets to expand the pipeline and portfolio.